Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 35675078.
- Also identified by DOI 10.1001/jamanetworkopen.2022.15984 and PMC identifier 9178430.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cohort study assesses the durability of protection against symptomatic COVID-19 among participants of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine trial.
Medical subject headings
- 2019-nCoV Vaccine mRNA-1273
- COVID-19